Scilex Holding Company Stock

Equities

SCLX

US80880W1062

Pharmaceuticals

Real-time Estimate Cboe BZX 10:27:43 2024-06-24 am EDT 5-day change 1st Jan Change
1.805 USD +3.14% Intraday chart for Scilex Holding Company -15.58% -11.03%
Sales 2024 * 60.09M Sales 2025 * 89.17M Capitalization 212M
Net income 2024 * -102M Net income 2025 * -95M EV / Sales 2024 * 3.53 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 2.38 x
P/E ratio 2024 *
-2.38 x
P/E ratio 2025 *
-3.6 x
Employees 106
Yield 2024 *
-
Yield 2025 *
-
Free-Float 43.81%
More Fundamentals * Assessed data
Dynamic Chart
1 day-10.71%
1 week+8.70%
Current month+62.04%
1 month+60.55%
3 months+21.53%
6 months+25.00%
Current year-14.22%
More quotes
1 week
1.70
Extreme 1.7
2.20
1 month
1.03
Extreme 1.0302
2.30
Current year
0.73
Extreme 0.7316
2.63
1 year
0.73
Extreme 0.7316
6.68
3 years
0.73
Extreme 0.7316
16.90
5 years
0.73
Extreme 0.7316
16.90
10 years
0.73
Extreme 0.7316
16.90
More quotes
Date Price Change Volume
24-06-24 1.815 +3.71% 158 246
24-06-21 1.75 -10.71% 2,878,596
24-06-20 1.96 +7.10% 2,150,494
24-06-18 1.83 -14.88% 2,698,428
24-06-17 2.15 +33.54% 5,680,794

Delayed Quote Nasdaq, June 21, 2024 at 04:00 pm EDT

More quotes
Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system) 1.8%, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It also focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. Its second commercial product ELYXYB, is a potential first-line treatment, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Its product candidates include SP-102 (SEMDEXA), SP-103 and SP-104. SP-102 is a viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica. Its SP-103 is a triple-strength formulation of ZTlido, for the treatment of chronic neck pain.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.75 USD
Average target price
5.333 USD
Spread / Average Target
+204.76%
Consensus